268 related articles for article (PubMed ID: 22643048)
1. Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma.
Péron J; Ceruse P; Lavergne E; Buiret G; Pham BN; Chabaud S; Favier B; Girodet D; Zrounba P; Ramade A; Fayette J
Anticancer Drugs; 2012 Oct; 23(9):996-1001. PubMed ID: 22643048
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck.
Vermorken JB; Licitra L; Stöhlmacher-Williams J; Dietz A; Lopez-Picazo JM; Hamid O; Hossain AM; Chang SC; Gauler TC
Eur J Cancer; 2013 Sep; 49(13):2877-83. PubMed ID: 23726971
[TBL] [Abstract][Full Text] [Related]
3. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
Baselga J; Trigo JM; Bourhis J; Tortochaux J; Cortés-Funes H; Hitt R; Gascón P; Amellal N; Harstrick A; Eckardt A
J Clin Oncol; 2005 Aug; 23(24):5568-77. PubMed ID: 16009950
[TBL] [Abstract][Full Text] [Related]
4. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
Herbst RS; Arquette M; Shin DM; Dicke K; Vokes EE; Azarnia N; Hong WK; Kies MS
J Clin Oncol; 2005 Aug; 23(24):5578-87. PubMed ID: 16009949
[TBL] [Abstract][Full Text] [Related]
5. Palliative weekly chemotherapy along with cetuximab in recurrent and metastatic head and neck cancers: a retrospective analysis.
Rangaraju RR; Sharma JB; Dewan AK; Anand AK; Sheh R; Jena A; Chaturvedi AK
Indian J Cancer; 2012; 49(1):1-5. PubMed ID: 22842160
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients.
Jiménez B; Trigo JM; Pajares BI; Sáez MI; Quero C; Navarro V; Llácer C; Medina L; Rueda A; Alba E
Oral Oncol; 2013 Feb; 49(2):182-5. PubMed ID: 23026069
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
Hussain M; Gadgeel S; Kucuk O; Du W; Salwen W; Ensley J
Cancer; 1999 Dec; 86(11):2364-9. PubMed ID: 10590379
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
Gibson MK; Li Y; Murphy B; Hussain MH; DeConti RC; Ensley J; Forastiere AA;
J Clin Oncol; 2005 May; 23(15):3562-7. PubMed ID: 15908667
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie.
Knoedler M; Gauler TC; Gruenwald V; Matzdorff A; Schroeder M; Dietz A; Jordan WO; Arnold D; Hennemann B; Hofele C; Weissinger F; Eberhardt W; Keilholz U
Oncology; 2013; 84(5):284-9. PubMed ID: 23445718
[TBL] [Abstract][Full Text] [Related]
11. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.
Vermorken JB; Herbst RS; Leon X; Amellal N; Baselga J
Cancer; 2008 Jun; 112(12):2710-9. PubMed ID: 18481809
[TBL] [Abstract][Full Text] [Related]
12. Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
Schena M; Barone C; Birocco N; Dongiovanni D; Numico G; Colantonio I; Bertetto O
Cancer Chemother Pharmacol; 2005 Mar; 55(3):271-6. PubMed ID: 15592837
[TBL] [Abstract][Full Text] [Related]
13. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer.
Bossi P; Kornek G; Lanzetta G; Rozzi A; Füreder T; Locati L; Licitra L
Head Neck; 2013 Oct; 35(10):1471-4. PubMed ID: 23042567
[TBL] [Abstract][Full Text] [Related]
14. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
[TBL] [Abstract][Full Text] [Related]
15. Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Lin CC; Yeh KH; Yang CH; Hsu C; Tsai YC; Hsu WL; Cheng AL; Hsu CH
Anticancer Drugs; 2007 Jul; 18(6):703-8. PubMed ID: 17762400
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Ginsberg L; Lawhorn K; Hong WK; Lippman SM
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-33-S19-37. PubMed ID: 9427263
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
18. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
Kiyota N; Tahara M; Kadowaki S; Fuse N; Doi T; Minami H; Ohtsu A
Jpn J Clin Oncol; 2009 Apr; 39(4):225-30. PubMed ID: 19211574
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
[TBL] [Abstract][Full Text] [Related]
20. TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
Strojan P; Grašič Kuhar C; Žumer B; Kadivec M; Karner K; Fajdiga I; Jančar B; Gale N; Poljak M; Kocjan BJ; Zakotnik B
Head Neck; 2014 Nov; 36(11):1555-61. PubMed ID: 24123552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]